GSK Australia
- The GSK shingles vaccine, Shingrix, will be available to eligible people via the National Immunisation Program (NIP) on 1 November 2023.
- There are more than four million Australians aged 65 years and over. Many of these will now be eligible for a new funded vaccine against shingles.
- Shingrix is the first non-live vaccine to be listed on the National Immunisation Program (NIP) for the prevention of shingles.1
- Shingrix is indicated for adults from the age of 50 years and above, and adults from the age of 18 years and above who are at increased risk of shingles.2*
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).
